Author(s): Keiji Sugiura and Mariko Sugiura
The up regulation of anti-tumor responses by immune-checkpoint blockade is a new approach for the treatment of advanced solid malignant tumors. There are some demerits to this therapy that require an evaluation of eligibility and efficacy, balanced against adverse effects and cost. Treatment for patients without immune checkpoint receptors or ligands remains an issue of concern. The cost of this therapy is huge and is further increased when treatment is required for adverse effects. The appropriate use of immune checkpoint therapy requires careful consideration.
